Platelet count or bleeding as the outcome in ITP trials

American Journal of Hematology

Volumn 87, Issue 10, 2012, Pages 945-946

  Arnold, Donald M ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b CANADIAN BLOOD SERVICES   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ELTROMBOPAG; ROMIPLOSTIM;

BLEEDING; BLEEDING TENDENCY; CORRELATION ANALYSIS; IMMUNE THROMBOCYTOPENIA; NOTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE;

BENZOATES; CLINICAL TRIALS AS TOPIC; HEMORRHAGE; HUMANS; HYDRAZINES; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; PYRAZOLES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, FC; RECOMBINANT FUSION PROTEINS; THROMBOPOIETIN;

EID: 84866767903     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.23299     Document Type: Note

References (16)

1. Neunert C, Lim W, Crowther M, et al. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood 2011; 117: 4190-4207.
2. Altomare I, Wasser J, Pullarkat V. Bleeding and mortality outcomes in ITP clinical trials: an analysis or thrombopoietin mimetics data. Am J Hematol 2012.
3. Arnold DM, Lim W. The use and abuse of surrogate endpoints in clinical research in transfusion medicine. Transfusion 2008; 48: 1547-1549.
4. Bucher HC, Guyatt GH, Cook DJ, et al. Users' guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points. Evidence-Based Medicine Working Group. JAMA 1999; 282: 771-778.
5. Slichter SJ. Relationship between platelet count and bleeding risk in thrombocytopenic patients. Transfus Med Rev 2004; 18: 153-167.
6. Lacey JV, Penner JA. Management of idiopathic thrombocytopenic purpura in the adult. Semin Thromb Hemostat 1977; 3: 160-174.
7. Buchanan GR, Adix L. Grading of hemorrhage in children with idiopathic thrombocytopenic purpura. J Pediatr 2002; 141: 683-688.
8. Khellaf M, Michel M, Schaeffer A, et al. Assessment of a therapeutic strategy for adults with severe autoimmune thrombocytopenic purpura based on a bleeding score rather than platelet count. Haematologica 2005; 90: 829-832.
9. Page LK, Psaila B, Provan D, et al. The immune thrombocytopenic purpura (ITP) bleeding score: assessment of bleeding in patients with ITP. Br J Haematol 2007; 138: 245-248.
10. Kuter DJ, Rummel M, Boccia R, et al. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med 2010; 363: 1889-1899.
11. Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): A 6-month, randomised, phase 3 study. Lancet 2011; 377: 393-402.
12. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
13. Heddle NM, Arnold DM, Webert KE. Time to rethink clinically important outcomes in platelet transfusion trials. Transfusion 2011; 51: 430-434.
14. Neunert CE, Buchanan GR, Imbach P, et al. Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura. Blood 2008; 112: 4003-4008.
15. Zeng Y, Duan X, Xu J, Ni X. TPO receptor agonist for chronic idiopathic thrombocytopenic purpura. Cochrane Database Syst Rev 2011; 7:CD008235.
16. Tunis SR, Benner J, McClellan M. Comparative effectiveness research: Policy context, methods development and research infrastructure. Stat Med 2010; 29: 1963-1976.